Psychotherapeutic Benefits of Opioid Agonist Therapy

Journal of Addictive Diseases

Volumn 27, Issue 3, 2008, Pages 49-65

  Tenore, Peter L ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Anxiety; Co morbidity; Depression; Methadone; Opioid; Psychiatric

Indexed keywords

AMITRIPTYLINE; BETA ENDORPHIN; BUPRENORPHINE; CITALOPRAM; DEXTROMETHORPHAN; DEXTROPROPOXYPHENE; DOPAMINE; ENDORPHIN; ESCITALOPRAM; ETHAVERINE; FLUOXETINE; IMIPRAMINE; KETAMINE; LAMOTRIGINE; LORAZEPAM; METHADONE; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NORTRIPTYLINE; OPIATE AGONIST; OPIATE DERIVATIVE; OXYCODONE; PAPAVERINE; PAROXETINE; PETHIDINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; NARCOTIC AGENT; NEUROTRANSMITTER RECEPTOR;

ANXIETY; ANXIETY DISORDER; BIPOLAR DISORDER; CLINICAL TRIAL; DEPRESSION; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; HUMAN; LOW DRUG DOSE; MAINTENANCE THERAPY; MENTAL DISEASE; METHADONE TREATMENT; MOOD; NEUROMODULATION; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; OPIATE ADDICTION; PATIENT COMPLIANCE; PATIENT SATISFACTION; PSYCHOPHARMACOTHERAPY; REVIEW; REWARD; SCHIZOIDISM; SEIZURE; SEROTONIN RELEASE; SINGLE DRUG DOSE; TREATMENT DURATION; BRAIN; COMORBIDITY; DOSE RESPONSE; PSYCHIATRIC DIAGNOSIS; PSYCHOLOGICAL ASPECT;

ANXIETY DISORDERS; BRAIN; BUPRENORPHINE; COMORBIDITY; DEPRESSIVE DISORDER; DIAGNOSIS, DUAL (PSYCHIATRY); DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; METHADONE; NARCOTICS; OPIOID-RELATED DISORDERS; RECEPTORS, NEUROTRANSMITTER;

EID: 58149145632     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1080/10550880802122646     Document Type: Review

References (88)

1. Hodgson B. Opium: A Portrait of a Heavenly Demon. San Francisco: Chronicle Books; 1999.
2. Bendick J. Galen and the Gateway to Medicine. Bathgate, ND: Bethlehem Books; 2002.
3. De Quincey T. Confessions of an English Opium Eater (1822). London: Penguin Classics; 2003.
4. White WL. Slaying the Dragon: The History of Addiction in America. Bloomington, IL: Chesnut Health Systems Publications; 1998.
5. Harrison Narcotic Tax Act. Public Law No. 223, 63rd Cong., approved December 17, 1914.
6. Varga E. The effect of codeine on involutional and senile depression. Ann N Y Acad Sci. 1982;398:103-5.
7. Kraepelin E. Einführung in die psychiatrische Klinik: zweiunddreissig Vorlesungen. Leipzig: J.A. Barth; 1905.
8. Belluzzi J, Stein L. Enkephaline may mediate euphoria and drive-reduction reward. Nature. 1977;266(5602): 556-8.
9. Ikemoto S, Panksepp J. The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking. Brain Res Rev. 1999;31(1):6-41.
10. Gross-Isseroff R, Dillon K, Israeli M, Biegon A. Regionally selective increases in mu opioid receptor density in the brains of suicide victims. Brain Res. 1990;530(2): 312-6.
11. Naber D, Pickar D, Post R, Van Kammen D, Waters R, Ballenger J, Goodwin F, Bunney W. Endogenous opioid activity and beta-endorphin immunoreactivity in CSF of psychiatric patients and normal volunteers. Am J Psychiatry. 1981;138(11):1457-62.
12. Sweetmen SC, Blake PS, McGlashan JM, Neathercoat GC, Parsons AV, eds. Martindale: The Complete Drug Reference. 35th Edition. London: Pharmaceutical Press; 2006.
13. Halbreich M, Endicott J. Possible involvement of endorphin withdraw in postpartum depression. Medical Hypotheses. 1981;7:1054-8.
14. Emrich H, Vogt P, Herz A. Possible antidepressive effects of opioids: Action of buprenorphine. Ann N Y Acad Sci. 1982;398:108-12.
15. Bodkin J, Alexander M, Zornberg G, Lukas S, Cole J. Buprenorphine treatment of refractory depression. Jour of Clin Psychopharm. 1995;15(1):49-57.
16. Resnick R, Falk F. Buprenorphine: Pilot trials in borderline patients and opiate dependence. In: Harris LB, ed. NIDA Research Monograph: Problems of Drug Dependence. Washington, D.C.: U.S. Government Printing Office; 1987.
17. Callawaye E. Buprenorphine for depression. Biological Psychiatry. 1996;39(12):989-90.
18. Morgan L, Callowaye E. Buprenorphine responders. Biological Psychiatry. 1990;28:1078-80.
19. Kosten T, Morgan C, Kosten T. Depressive symptoms during buprenorphine treatment of opioid abusers. J Subst Abuse Treat. 1990;7(1):51-4.
20. Maremmani I, Pacini M, Pani P. Effectiveness of buprenorphine in double diagnosed patients. Buprenorphine as a psychotropic drug. Heroin Add Rel Clin Probl. 2006;8(1):31-48.
21. Dean A, Bell J, Christie M, Mattick R. Depressive symptoms during buprenorphine vs. methadone maintenance: findings from a randomised, controlled trial in opioid dependence. Eur Psychiatry. 2004;19(8):510-3.
22. Dean A, Bell J, Mascord D, Parker G, Macdonald C. A trial of fluoxetine in methadone maintenance patients with depression. J Aff Disord. 72:1;85-90.
23. Dyer K, White J, Foster D, Bochner F, Memelaou A, Somogyi A. Mood state and methadone plasma concentrations. J Clin Psychopharm. 2001;21(1):78-84.
24. McNair DM, Lorr M, Droppelman LF. Profile of Mood States Manual. San Diego, CA: Educational and Industrial Testing Service; 1992.
25. De Montis, G, Devoto P, Tagliamonte A. Possible antidepressant activity of methadone. Euro J Pharm. 1892;79(1-2);145-6.
26. Drevets W, Frank E, Price J, Kupfer D, Holt D, Greer P, Huang Y, Gautier C, Mathis C. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry. 1999;46(10):1375-87.
27. Rosa-Neto P, Diksic M, Okazawa H, Leyton M, Ghadirian N, Mzengeza S, Nakai A, Debonnel G, Blier P, Benkelfat C. Measurement of brain regional alpha-[11C]methyl-L-tryptophan trapping as a measure of serotonin synthesis in medication-free patients with major depression. Arch Gen Psychiatry. 2004;61(6):556-63.
28. Neumeister A, Bain E, Nugent A, Carson R, Bonne O, Luckenbaugh D, Eckelman W, Herscovitch P, Charney D, Drevets W. Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci. 2004;24(3):589-91.
29. Williams J, Mulrow C, Chiquette E, Noel P, Aguilar C, Cornell J. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med. 2000;132(9):743-56.
30. Ciofalo F. Methadone inhibition of 5-hydroxytryptamine uptake. J Pharmacol Exp Ther. 1974;189(1):83-9.
31. Gillman P. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth. 2005;95(4):434-41.
32. Maremmani I, Matteo P, Lubrano S, Lovreded M, Perugi G. Dual diagnosis heroin addicts: the clinical and therapeutic aspects. Heroin Add Rel Clin Probl. 2003;5(2):7-98.
33. Hamilton S, Nunes E, Janal M, Weber L. The Effect of sertraline on methadone plasma levels in methadone maintenance patients. Am J Addict. 2000;9:63-9.
34. Eap C, Gilles M, Powell K, Baumann P. Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of enantiomers of methadone. J Clin Psychopath. 1997;17(2):113-7.
35. Berge S, von Bardeleben U, Ladewig D, Jaquet S, Cosendai L, Golay K, Kosel M, Baumann P, Eap C. Paroxetine increases steady state concentrations of methadone. J Clin Psychopharmacol. 2002;22(2):211-5.
36. Waugh J, Goa K. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs. 2003;17:343-62.
37. Meyer JH, Ginovart N, Boovariwala A, Boovariwala A, Sagrati S, Hussey D, Garcia A, Young T. Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry. 2006;63(11):1209-16.
38. VanderWende C, Spoerlein M. Effect of narcotics on monoamine oxidase activity of mouse brain. Res Chem Pathol Pharmacol. 1979;24(1):103-13.
39. Lee S, Lee J, Cheong M, Kim H, Kim Y, Yun Y, Lee C, Lee M. Inhibitory effects of ethaverine on monoamine oxidase activity in mouse brain. Biol Pharm Bull. 2001;24(7):838-40.
40. Sachar E, Hellman L, Roffwarg H, Halpern F, Fukushima D, Gallagher T. Disrupted 24-hour patterns of cortisol secretion in psychotic depression. Arch Gen Psychiatry. 1973;28(1):19-24.
41. Gold P, Extein I, Pickar D, Rebar R, Ross R, Goodwin F. Supression of plasma cortisol in depressed patients by acute intravenous methadone infusion. Am J Psychiatry. 1980;137(7):862-3.
42. Judd L, Parker D, Janowsky D, Segal D, Risch S, Huey L. The effect of methadone on the behavioral and neuroendocrine responses of manic patients. Psychiatry Res. 1982;7(2):163-70.
43. Paul I, Skolnick P. Glutamate and depression. Ann N Y Acad Sci. 2003;1003:250-7.
44. Bergink V, van Megen H, Westenberg H. Glutamate and anxiety. Eur Neuropsychopharmacol. 2004;14(3): 175-83.
45. Callahan R, Au J, Liu C, Yost C. Functional inhibition by methadone of NMDA receptors. Anesth Analg. 2004;98(3):653-9.
46. Zarate C, Singh J, Carlson P, Brutsche N, Ameli R, Luckenbaugh D. A randomized trial of NMDA antagonist in major depression. Arch Gen Psychiatry. 2006;63(8):856-64.
47. Gorman A, Elliott K, Inturrisi C. The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci Lett. 1997;223(1): 5-8.
48. Berman R, Cappiello A, Anand A, Oren D. Antidepressant effects of ketamine in depressed patients. Biol Psych. 2000;47(4):351-4.
49. Ebert B, Andersen S, Krogsgaard P. Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett. 1995;187(3):165-8.
50. Davis A, Inturrisi C. Methadone blocks morphine tolerance and NMDA induced hyperalgesia. Pharmacol and Exper Therap. 1999;289(2):1048-53.
51. Pani P, Trogu E, Carboni G, Palla P, Loi A. Psychiatric severity and treatment response in methadone programs. Heroin Add Rel Clin Probl. 2003;5(3):23-36.
52. Maremmani I, Zolesi O, Agueci T, Castrogiovanni P. Methadone doses and psychopathological symptons during methadone maintenance. J Psychoact Drug. 1993;25(3):253-6.
53. Pani P, Trogu E, Contu P, Agus A, Gessa G. Psychiatric severity and treatment response in a comprehensive methadone maintenance treatment program. Drug Alcohol Depend. 1997;48(2):119-26.
54. Lomas L, Picker M, Behavioral assessment of temporal summation in the rat: sensitivity to sex, opioids and modulation by NMDA receptor antagonists. Psychopharmacology (Berl). 2005;180(1):84-94.
55. Tatarczynska E. Potential anxiolytic effects of MPEP. Br J Pharmacol. 2001;132(7):1423-30.
56. Mirza N, Bright J, Stanhope K, Wyatt A, Harrington N. Lamotrignine has an anxiolytic-like profile in rats. Psychopharmacology. 2005;180(1):159-68.
57. Klodzinska A, Tatarczynska E. Anxiolytic effects of MTEP. Neuropharmacology. 2004 Sep; 47(3):342-50.
58. Becqet D, Hery M, Francois A, Giraud P, Deprez P, Faudon M, Fache M, Hery F. Glutamate, GABA, glycine and taurine modulate serotonin synthesis and release in rostral and caudal rhombencephalic raphe cells in primary cultures. Neurochem Int. 1993;23(3):269-83.
59. Rybakowski J. Long-term pharmacological treatment of bipolar disorders. Neuro Endocrinol Lett. 2007; 28(Suppl1):71-93.
60. Rosenberg D, MacMaster F, Keshavan M, Fitzgerald K, Stewart C, Moore G. Decrease in Caudate Glutamate in OCD. J Am Acad Child Adol Psych. 2000;39(9):1096-103.
61. Owen J, Whitton P. Chronic treatment with antidepressants reverses NMDA mediated regulation of 5-HT in rat brain. Brain Res Bull. 2006;70(1):62-7.
62. Stachowicz K, Chojnacka E, Klak K, Pilc A. Anxiolytic-like effect of group III mGlu receptor antagonist is serotonin-dependent. Neuropharmacology. Feb;52(2):306-12.
63. Goldsmith M, Shapira N, Keck P. Rapid remission of OCD with tramadol hydrochloride. Am J Psychiatry. 1999;156:660-1.
64. Shapira N, Keck P, Golsdmith T, McConville B, Eis M, McElroy S. Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder. Depress Anxiety. 1997;6(4):170-3.
65. Khazaal Y, Krenz M, Zullino D. Worsening of OCD symptome under methadone tapering. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(7):350-2.
66. Zhu W, Pan Z. Mu-opioid-mediated inhibition of glutamate synaptic transmission in rat central amygdala neurons. Neuroscience. 2005;133(1):97-103.
67. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders., 4th Edition, Text Revision. Washington, D.C.: Author; 2000.
68. Peles E, Schreiber S, Adelson M. Factors predicting retention in treatment: 10-year experience of a methadone maintenance treatment (MMT) clinic in Israel. Drug Alcohol Depend. 2006;82(3):211-7.
69. Mason B, Kocsis J, Melia D, Khuri E, Sweeney J, Wells A, Borg L, Millman R, Kreek M. Psychiatric comorbidity in methadone maintained patients. J Addic Diseas. 1998;17(3):75-89.
70. Peles E, Schreiber S, Naumovsky Y, Adelson M. Depression in methadone maintenance treatment patients. J Affect Disord. 2006; [Epub ahead of print].
71. Ross J, Teesson M, Darke S, Lynskey M, Ali R, Ritter A, Cooke R. The characteristics of heroin users entering treatment: findings from the Australian treatment outcome study (ATOS). Drug Alcohol Rev. 2005;24(5):411-8.
72. Maremmani I, Zolesi O, Agletti M, Tagliamonte A, Shinderman M, Maxwell S. Methadone dose and retention during treatment of heroin addicts with axis 1 psychiatric comorbidity. J Addic Dis. 2000;19(2):29-41.
73. Villafranca S, Mckellar J, Trafton J, Humphreys K. Predictors of retention in methadone programs: a signal detection analysis. Drug Alcohol Depend. 2006;83(3): 218-24.
74. Farre M, Mas A, Torrens M, Moreno V, Cami J. Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. Drug Alcohol Depend. 2002;65(3):283-90.
75. Brady T, Salvucci S, Sverdlov L, Male A, Kyeyune H, Sikali E, DeSale S, Yu P. Methadone dosage and retention: an examination of the 60 mg/day threshold. J Addict Dis. 2005;24(3):23-47.
76. Maxwell S, Schinderman M. Optimizing long-term response to methadone maintenance treatment: a 152-week follow-up using higher-dose methadone. J Addict Dis. 2002;21(3):1-12.
77. Torres M, Castillo C, Perez V. Retention in a low-threshold methadone maintenance program. Drug Alcohol Depend. 1996;41(1):55-9.
78. Trafton J, Minkel J, Humphreys K. Determining effective methadone doses for individual dependent patients. PLoS Med. 2006;3(3):80-94.
79. Tenore P. CARF Review Data File, Oct 2000, Albert Einstein College of Medicine, Division of Substance Abuse, Division of Psychiatry, data on file.
80. Matteo P, Maremanni I. Methadone reduces need for psychiatric agents in heroin addicts hospitalized for panic and/or acute psychotic episodes. Heroin Add & Rel Clin Probl. 2005;7(4):43-8.
81. Cacciola J, Alterman A, Rutherford M, McKay J, Mulvaney F. The relationship of psychiatric comorbidity to treatment outcomes in methadone maintained patients. Drug Alcohol Depend. 2001;61(3):271-80.
82. Treece C, Nicholson B. Personalilty type and dose levels in methadone maintenance. J Nerv Ment Dis. 1980;168(10):621-8.
83. Bleich A, Gelkopf M, Weizman T, Adelson M. Benzodiazepine abuse in a methadone maintenance treatment clinic in Israel: characteristics and a pharmacotherapeutic approach. Isr J Psychiatry Relat Sci. 2002;39(2):104-12.
84. Tenore P. CARF Review Data File, Oct 2006, Albert Einstein College of Medicine Division of Substance Abuse, Division of Psychiatry, data on file.
85. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, Pettinati H, Argeriou M. The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9(3):199-213.
86. Nunes E, Quitkin F, Brady R, Post-Koenig T. Antidepressant treatment in methadone maintenance patients. J Addict Dis. 1994;13(3):13-24.
87. O'Connor P, Selwyn P , Schottenfeld R. Medical care for injection-drug users. N Engl J Med. 1994;331(7): 450-9.
88. National Consensus Development Panel on Effective Treatment of Opiate Addiction. JAMA. 1998;280: 1936-43.